The Board of Directors has evaluated subsequent events from the period-end through to 9 September 2026, which is the date the interim consolidated financial statements were authorised for issue. Subsequent to the period-end, the Company exercised the £75 million accordion agreed under the existing facility terms, with Board and lender approval, thereby increasing the total facility limit to £400 million.
No other event has been identified for disclosure.
